ClinicalTrials.gg
Not yet recruitingNCT07712653Updated Jul 21, 2026

Effects of Creatine and Carbohydrate Supplementation on Endurance Performance

An interventional study of Creatine Monohydrate and Carbohydrate in Exercise Performance Recovery, sponsored by California Polytechnic State University-San Luis Obispo. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by California Polytechnic State University-San Luis Obispo · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

This study will examine the independent and combined effects of creatine and carbohydrate supplementation on exercise performance, compared to placebo.

02

Conditions studied

  • Exercise Performance Recovery
03

In context

Lead sponsor

California Polytechnic State University-San Luis Obispo is the lead sponsor of 29 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • healthy (i.e. no known cardiovascular disease)
  • nonsmoking
  • active (regular physical activity ≥150 minutes per week of aerobic exercise and have a VO2 peak ≥35 ml/kg-min)
  • a normal (18.5 - 35 kg/m\^2)
  • between ages 18-40 years old

Exclusion criteria

Exclusion Criteria:

  • previously taken creatine and/or any other dietary supplement that may interfere with exercise performance
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
12 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Flavored water every 20 minutes

    Dietary Supplement: placebo solution

  • Experimental
    Creatine monohydrate

    Creatine Monohydrate supplementation every 0.5 grams every 20 minutes

    Dietary Supplement: Creatine Monohydrate

  • Experimental
    Carbohydrate

    Carbohydrate supplementation 5 grams every 20 minutes

    Dietary Supplement: Carbohydrate

  • Experimental
    Creatine and Carbohydrate

    Creatine supplementation at 0.5 gram and carbohydrate supplementation of 5 grams every 20 minutes

    Dietary Supplement: Creatine Monohydrate and Carbohydrate

Interventions

06

What researchers measure

Primary outcomes

  1. Exercise Time to exhaustion

    Time to exhaustion (seconds) during continuous cycling performed at 60% of each participant's maximal cycling power output following supplementation with placebo, creatine monohydrate, or creatine monohydrate plus carbohydrate.

    Time frame: Change in exercise time to exhaustion ( in seconds) through study completion, over the course of study completion, on average 4 weeks.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — IPD will be available on the Cal Poly Digital Commons website and available upon request.

Supporting information: Study protocol, Informed consent form

Time frame: August 1, 2026

Access criteria: Available to download

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2026; primary completion for Aug 2026, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2026
First posted
Jul 17, 2026
StartEst.
Jul 15, 2026
Primary completionEst.
Aug 1, 2026
CompletionEst.
Aug 1, 2026
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07712653
Lead sponsor
California Polytechnic State University-San Luis Obispo
Responsible party
Todd Hagobian (Department Chair and Professor, California Polytechnic State University-San Luis Obispo) — Principal investigator
First posted
Jul 17, 2026
Start date
Jul 15, 2026 (estimated)
Primary completion
Aug 1, 2026 (estimated)
Completion
Aug 1, 2026 (estimated)
Last update
Jul 21, 2026

Study contacts

Todd Hagobian, PhD
Contact
thagobia@calpoly.edu
805-756-7511

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Creatine monohydrate · Carbohydrates

Start the discussion